AOD 9604: Advanced Obesity Drug (modified Peptide Fragment of HGH)   Purity: 98% (HPLC on request)  
Molecular Formula : CC78H123N23O23S2   Molecular Weight: 1815.1    CAS No.:N/A 
Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

MolecularStructure Description

AOD 9604 is a modified form of amino acids 176-191 of the GH polypeptide. Investigators at

Monash University discovered that the fat-reducing effects of GH appear to be controlled by a small region near one end of the GH molecule. This region, which consists of amino acids 176-191, is less than 10% of the total size of the GH molecule and appears to have no effect on growth or insulin resistance. It works by mimicking the way natural Growth Hormone regulates fat metabolism but without the adverse effects on blood sugar or growth that is seen with unmodified Growth Hormone. Like Growth Hormone, AOD 9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis (the transformation of nonfat food materials into body fat) both in laboratory testing and in animals and humans. Recent findings have shown, in addition to its fat loss properties, AOD 9604 processes many other regenerative properties associated with growth hormone. Currently trials are underway to show the application of AOD 9604 in osteoarthritis, hypercholesterolemia, bone and cartilage repair. AOD 9604 has an excellent safety profile, recently obtaining Human GRAS status in the USA.

MicroscopeClinical Research

Safety and Tolerability of the Hexadecapeptide AOD 9604 in Humans

Heike Stier, Evert Vos, David Kenley

Background: The human growth hormone (hGH) has fat loss properties making it a potential candidate to treat obesity. AOD 9604 is a peptide fragment of the C-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD 9604 obtained in clinical trials are summarized.

 Methods: Six randomized, double-blind, placebo-controlled trials were performed with AOD 9604. Special focus was given to undesired effects associated with hGH treatment: increases in IGF-1 levels, insulin resistance, and impaired glucose tolerance. Blood samples were analyzed for presence of anti-AOD 9604 antibodies to exclude immunogenicity.

Results: AOD 9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD 9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD 9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD 9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD 9604.

 Conclusion: AOD 9604 displayed a very good safety and tolerability profile indistinguishable from placebo. AOD 9604 did not result in any of the adverse effects associated with full-length hGH treatment.

A full copy of all trials are available from Como Compounding Pharmacy. Please contact us for more information.

Download this information.